Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study-Reference-Cited by-同舟云学术

Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

Published:2022-10-21 Issue:12 Volume:78 Page:1973-1979
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Yekedüz Emre,Özbay Mehmet Fatih,Çağlayan Dilek,Yıldırım Atila,Erol Cihan,Yıldırım Hasan Çağrı,Tunç Sezai,Özyurt Neslihan,Özdemir Feyyaz,Şendur Mehmet Ali Nahit,Işıkdoğan Abdurrahman,Kılıçkap Saadettin,Ürün Yüksel,Yalçın Şuayib,Artaç Mehmet,Coşkun Hasan Şenol,Utkan Güngör

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00228-022-03403-1.pdf

Reference27 articles.

1. Kudo M (2020) Recent advances in systemic therapy for hepatocellular carcinoma in an aging society: 2020 Update. Liver Cancer 9(6):640–662. https://doi.org/10.1159/000511001

2. Crona DJ, Keisler MD, Walko CM (2013) Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors. Ann Pharmacother 47(12):1685–1696. https://doi.org/10.1177/1060028013509792

3. Shirley M, Keating GM (2015) Regorafenib: a review of its use in patients with advanced gastrointestinal stromal tumours. Drugs 75(9):1009–1017. https://doi.org/10.1007/s40265-015-0406-x

4. Gay C, Toulet D, Le Corre P (2017) Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: a focus on cytochrome P450, transporters, and acid suppression therapy. Hematol Oncol 35(3):259–280. https://doi.org/10.1002/hon.2335

5. Yin OQ, Gallagher N, Fischer D, Demirhan E, Zhou W, Golor G, Schran H (2010) Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol 50(8):960–967. https://doi.org/10.1177/0091270009346061

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure;ESMO Open;2023-02